Keeping the Workforce: the Drug Industry's Cognitive Dissonance Problem
Executive Summary
Amidst the mounting attacks on the drug industry by respected mass market publications and broadcast news, it is growing increasingly difficult for those in the industry to maintain the personal mission of "doing good" that--at least partly--attracted them to the pharmaceutical business. In the past, attractive option packages might have helped executives deal with uneasiness about some of the strategies being pursued by companies under the gun of blockbuster economics. But with stock prices low, that source of comfort has been removed--raising doubts about the industry's ability to retain its best and brightest.
You may also be interested in...
The Value of Me-Too's in the Context of OTC Switches
At Windhover's annual Marketing Pharmaceutical Innovation (MPI) conference in November, industry executives wrestled with an emerging dilemma -- how to win managed care's support for drugs that exhibit only minor improvements to existing products, while new over-the-counter (OTC) options surface.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.